HighTower Advisors
ESPR

HighTower Advisors’s Esperion Therapeutics ESPR Stock Holding History

HighTower Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.1K Sell
13,021
-128,131
-91% -$358K ﹤0.01% 3739
2026
Q1 		$387K Buy
141,152
+27,253
+24% +$86.3K ﹤0.01% 2943
2025
Q4 		$421K Sell
113,899
-6,112
-5% -$19.8K ﹤0.01% 2763
2025
Q3 		$318K Buy
120,011
+1,672
+1% +$3.23K ﹤0.01% 2997
2025
Q2 		$116K Sell
118,339
-6,547
-5% -$6.56K ﹤0.01% 3438
2025
Q1 		$180K Buy
124,886
+20,625
+20% +$38K ﹤0.01% 3224
2024
Q4 		$229K Sell
104,261
-1,310
-1% -$3.06K ﹤0.01% 3098
2024
Q3 		$176K Sell
105,571
-131,214
-55% -$265K ﹤0.01% 3179
2024
Q2 		$514K Buy
236,785
+49,619
+27% +$117K ﹤0.01% 2298
2024
Q1 		$496K Buy
187,166
+137,597
+278% +$334K ﹤0.01% 2293
2023
Q4 		$149K Buy
49,569
+25,211
+104% +$32.7K ﹤0.01% 3094
2023
Q3 		$23K Buy
24,358
+765
+3% +$1.11K ﹤0.01% 3314
2023
Q2 		$32K Buy
+23,593
New +$32.9K ﹤0.01% 3211
2020
Q4 		– Sell
-32,753
Closed -$1.22M – 2684
2020
Q3 		$1.22M Buy
32,753
+12,185
+59% +$483K 0.01% 1114
2020
Q2 		$1.06M Sell
20,568
-25
-0.1% -$1.05K 0.01% 1091
2020
Q1 		$650K Sell
20,593
-1,275
-6% -$67.3K ﹤0.01% 1211
2019
Q4 		$1.3M Buy
21,868
+1,519
+7% +$68.3K 0.01% 1019
2019
Q3 		$744K Sell
20,349
-7,766
-28% -$308K ﹤0.01% 1330
2019
Q2 		$1.3M Buy
28,115
+8,926
+47% +$419K 0.01% 1068
2019
Q1 		$770K Buy
19,189
+1,228
+7% +$55.1K 0.01% 1252
2018
Q4 		$825K Buy
17,961
+411
+2% +$19.8K 0.01% 1123
2018
Q3 		$778K Buy
+17,550
New +$806K 0.01% 1245

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

HighTower Advisors's ESPR Position: Q2 2026 in Review

HighTower Advisors reduced its Esperion Therapeutics (ESPR) stake by 91% in Q2 2026, selling an estimated $358K and leaving 13,021 shares worth $41.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3739.

HighTower Advisors first reported a position in ESPR in Q3 2018 and has held it in 22 quarters since. The position peaked at $1.3M in Q2 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • HighTower Advisors held 13,021 shares of Esperion Therapeutics worth $41.1K as of Q2 2026.
  • HighTower Advisors sold 128,131 Esperion Therapeutics shares in Q2 2026, an estimated $358K.
  • Esperion Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3739 holding.
  • HighTower Advisors first reported a position in Esperion Therapeutics in Q3 2018 and has held it in 22 quarters since.
  • HighTower Advisors's Esperion Therapeutics position peaked at $1.3M in Q2 2019.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.